8-K: Becton, Dickinson and Company Reaches $9 Million Settlement in Stockholder Derivative Lawsuits, Enhances Corporate Governance

Becton, Dickinson and Company (BD) has announced a proposed settlement of consolidated stockholder derivative actions, including a $9 million payment funded by D&O insurance and the implementation of new corporate governance modifications.

Summary

• Becton, Dickinson and Company (BD) has reached a proposed settlement in the consolidated stockholder derivative actions, including 'In re Becton, Dickinson and Company Stockholder Derivative Litigation' and 'Lotz v. Burzik, et al.'.
• The settlement includes a payment of $9,000,000 to the Settlement Fund, which will be paid by BD's Directors and Officers (D&O) insurance carriers, with no monetary outlay by the Company above its self-insured retention.
• BD has agreed to adopt certain corporate Governance Modifications within sixty (60) days of the final approval order, which it will maintain for a period of not less than four (4) years.
• The Derivative Actions alleged that Individual Defendants breached fiduciary duties by making allegedly false and misleading statements between November 5, 2019, and February 5, 2020, regarding software defects and modifications in BD's Alaris infusion pump system, FDA scrutiny, and the potential financial impact.
• Plaintiffs also alleged that certain officers and directors sold BD stock at artificially inflated prices based on material non-public information.
• The settlement, if approved, will fully and finally resolve the Consolidated Federal Derivative Action and all related claims, leading to dismissal with prejudice.
• Plaintiffs' counsel will request attorneys' fees and expenses of $3,470,000, and may apply for service awards for Plaintiffs not exceeding $5,000 each, to be paid from the Fee and Expense Amount.
• A Settlement Hearing is scheduled for August 11, 2025, at 10:00 a.m. in the U.S. District Court for the District of New Jersey to determine the fairness and adequacy of the settlement.

Sentiment

Score: 7

Explanation: The settlement resolves significant and long-standing litigation, with the monetary component covered by D&O insurance, thereby limiting direct financial impact on the company. The commitment to implement and maintain corporate governance modifications is a positive step towards strengthening internal controls and mitigating future risks, contributing to overall stability and reduced uncertainty.

Positives

• The settlement resolves complex and long-standing stockholder derivative litigation, reducing legal uncertainty and potential future litigation costs for BD.
• The $9,000,000 monetary component of the settlement is funded by BD's D&O insurance carriers, meaning no direct cash outlay by the Company beyond its self-insured retention.
• BD will implement corporate Governance Modifications, which the Company acknowledges confer a material benefit and were influenced by the derivative actions, potentially strengthening internal controls and oversight.
• The settlement includes a full release of claims against the Individual Defendants, providing closure for the involved parties.

Negatives

• The underlying allegations involved serious claims of breaches of fiduciary duties, insider selling, and making false and misleading statements regarding the Alaris infusion pump system and FDA scrutiny.
• The litigation process itself incurred substantial time, expense, and disruption for the Company and its management.
• The settlement does not imply an admission of wrongdoing or liability by the Defendants, which may leave some stockholder concerns unaddressed regarding past conduct.

Risks

• The historical allegations highlight risks associated with regulatory scrutiny (specifically FDA) of medical devices and the potential for software defects to impact product viability and financial performance.
• While the current litigation is being settled, the effectiveness of the new corporate governance modifications in preventing similar issues in the future remains to be seen.
• The Company's reputation could have been negatively impacted by the allegations of misleading statements and insider selling, even with the settlement.

Future Outlook

BD has committed to adopting certain corporate Governance Modifications within 60 days of the final settlement approval and maintaining them for a period of not less than four years, indicating a forward-looking commitment to enhanced corporate oversight and risk management.

Management Comments

• The Company acknowledges that the initiation, pendency, and settlement of the Derivative Actions, and the Plaintiffs' efforts, were a material factor in the implementation of the Governance Modifications.
• The Company acknowledges that the Governance Modifications confer a material benefit on the Company.

Industry Context

This settlement highlights the significant regulatory and legal risks inherent in the medical device industry, particularly concerning product quality, software integrity, and compliance with regulatory bodies like the FDA. Allegations of misleading statements and insider trading underscore the importance of robust corporate governance and transparency in a highly regulated sector where product safety and efficacy are paramount.

Comparison to Industry Standards

• The resolution of stockholder derivative litigation through a settlement funded by Directors and Officers (D&O) insurance is a common practice in corporate legal affairs, allowing companies to resolve disputes without direct impact on operational cash flow beyond self-insured retention.
• The implementation of corporate governance modifications as part of a settlement is a standard approach to address alleged deficiencies and enhance oversight, aligning with best practices for corporate responsibility and risk mitigation in publicly traded companies.

Corporate Governance

Legal Proceedings

• Consolidated Federal Derivative Action: In re Becton, Dickinson and Company Stockholder Derivative Litigation, Master File No. 2:20-cv-15474-SRC-CLW (D.N.J.).
• Consolidated State Court Action: Lotz v. Burzik, et al., Docket No. BER-C-00174-24 (N.J. Sup. Ct. Bergen Cnty.), consolidated with Stein v. Burzik, et al., Case No. BER-C-000156-23 (CONSOLIDATED CASE BER-L -007001-24).
• Related Federal Securities Class Action: Industriens Pensionsforsikring A/S v. Becton, Dickinson and Company, et al., No. 2:20-cv-02155 (D.N.J. Feb. 27, 2020), which was previously settled and dismissed with prejudice on April 26, 2024.
• Allegations in Derivative Actions: Breaches of fiduciary duties and insider selling by Individual Defendants, making allegedly false and misleading statements regarding software defects and modifications in BD's Alaris infusion pump system, ongoing FDA scrutiny, and the potential impact on the Company's financial position.

Stakeholder Impact

• Shareholders: Current BD stockholders are directly impacted as the settlement resolves claims brought derivatively on their behalf. They benefit from the resolution of litigation and the implementation of corporate governance improvements. They also have the right to object to the proposed settlement terms.
• Company (BD): Benefits from the cessation of costly and disruptive litigation, avoiding further legal expenses and management distraction. The monetary payment is covered by D&O insurance, limiting direct financial impact.
• Individual Defendants: Released from all claims related to the derivative actions, providing legal closure.
• Employees: Indirectly benefit from the resolution of legal uncertainty, which can contribute to a more stable corporate environment.

Next Steps

• A Settlement Hearing will be held on August 11, 2025, at 10:00 a.m. to determine whether the settlement terms are fair, reasonable, and adequate, and to approve the final judgment and attorneys' fees/service awards.
• BD is required to adopt certain corporate Governance Modifications within sixty (60) days of the issuance of an order finally approving the settlement.
• BD shall maintain the adopted Governance Modifications for a period of not less than four (4) years.

Key Dates

Keywords

SEC filing, stockholder derivative action, settlement, corporate governance, Becton Dickinson, BD, Alaris infusion pump, FDA scrutiny, fiduciary duty, insider trading, D&O insurance, legal proceedings, 8-K filing